<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PPAR Res</journal-id><journal-id journal-id-type="iso-abbrev">PPAR Res</journal-id><journal-id journal-id-type="publisher-id">PPAR</journal-id><journal-title-group><journal-title>PPAR Research</journal-title></journal-title-group><issn pub-type="ppub">1687-4757</issn><issn pub-type="epub">1687-4765</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27403152</article-id><article-id pub-id-type="pmc">4923578</article-id><article-id pub-id-type="doi">10.1155/2016/7407153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhongxia</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Tao</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Lizhe</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ruifeng</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Yuanyuan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7002-4671</contrib-id><name><surname>Fan</surname><given-names>Xiaojuan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Zuyi</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Junhui</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Tao</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor2">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Cardiology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China</aff><aff id="I2"><sup>2</sup>Department of Medicine, Gansu Provincial Hospital of TCM, Lanzhou 730050, China</aff><aff id="I3"><sup>3</sup>Department of Cardiology, Xi'an Central Hospital, Xi'an 710003, China</aff><author-notes><corresp id="cor1">*Junhui Liu: <email>19445948@qq.com</email> and </corresp><corresp id="cor2">*Tao Chen: <email>chentaoxjtu@163.com</email></corresp><fn fn-type="other"><p>Academic Editor: Alexander N. Orekhov</p></fn></author-notes><pub-date pub-type="ppub"><year>2016</year></pub-date><pub-date pub-type="epub"><day>14</day><month>6</month><year>2016</year></pub-date><volume>2016</volume><elocation-id>7407153</elocation-id><history><date date-type="received"><day>23</day><month>12</month><year>2015</year></date><date date-type="rev-recd"><day>11</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2016 Zhongxia Wang et al.</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><offsets xml_i="4440" xml_f="4627" txt_i="11" txt_f="198">The inflammatory response after polymer-based drug-eluting stent (DES) placement has recently emerged as a major concern. The biologic roles of peroxisome proliferator-activated receptor-</offsets><italic><offsets xml_i="4635" xml_f="4636" txt_i="198" txt_f="199">γ</offsets></italic><offsets xml_i="4645" xml_f="4652" txt_i="199" txt_f="206"> (PPAR-</offsets><italic><offsets xml_i="4660" xml_f="4661" txt_i="206" txt_f="207">γ</offsets></italic><offsets xml_i="4670" xml_f="4931" txt_i="207" txt_f="468">) activators thiazolidinedione (TZD) remain controversial in cardiovascular disease. Herein, we investigated the antiinflammatory effects of pioglitazone (PIO) on circulating peripheral blood mononuclear cells (MNCs) in patients after coronary DES implantation.</offsets><italic><offsets xml_i="4939" xml_f="4959" txt_i="468" txt_f="488"> Methods and Results</offsets></italic><offsets xml_i="4968" xml_f="5332" txt_i="488" txt_f="852">. Twenty-eight patients with coronary artery disease and who underwent DES implantations were randomly assigned to pioglitazone (30 mg/d; PIO) or placebo (control; Con) treatment in addition to optimal standard therapy. After 12 weeks of treatment, plasma concentrations of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-</offsets><italic><offsets xml_i="5340" xml_f="5341" txt_i="852" txt_f="853">α</offsets></italic><offsets xml_i="5350" xml_f="5356" txt_i="853" txt_f="859"> (TNF-</offsets><italic><offsets xml_i="5364" xml_f="5365" txt_i="859" txt_f="860">α</offsets></italic><offsets xml_i="5374" xml_f="5485" txt_i="860" txt_f="971">), and matrix metalloproteinase-9 (MMP-9) were significantly decreased in PIO group compared to the Con group (</offsets><italic><offsets xml_i="5493" xml_f="5494" txt_i="971" txt_f="972">P</offsets></italic><offsets xml_i="5503" xml_f="5588" txt_i="972" txt_f="1057"> = 0.035, 0.011, 0.008, and 0.012, resp.). DES-induced mRNA expressions of IL-6, TNF-</offsets><italic><offsets xml_i="5596" xml_f="5597" txt_i="1057" txt_f="1058">α</offsets></italic><offsets xml_i="5606" xml_f="5672" txt_i="1058" txt_f="1124">, and MMP-9 in circulating MNC were significantly blocked by PIO (</offsets><italic><offsets xml_i="5680" xml_f="5681" txt_i="1124" txt_f="1125">P</offsets></italic><offsets xml_i="5690" xml_f="5778" txt_i="1125" txt_f="1213"> = 0.031, 0.012, and 0.007, resp.). In addition, PIO markedly inhibited DES-enhanced NF-</offsets><italic><offsets xml_i="5786" xml_f="5787" txt_i="1213" txt_f="1214">κ</offsets></italic><offsets xml_i="5796" xml_f="5828" txt_i="1214" txt_f="1246">B function and DES-blocked PPAR-</offsets><italic><offsets xml_i="5836" xml_f="5837" txt_i="1246" txt_f="1247">γ</offsets></italic><offsets xml_i="5846" xml_f="5888" txt_i="1247" txt_f="1289"> activity. Mechanically, DES induced PPAR-</offsets><italic><offsets xml_i="5896" xml_f="5897" txt_i="1289" txt_f="1290">γ</offsets></italic><offsets xml_i="5906" xml_f="5993" txt_i="1290" txt_f="1377"> ubiquitination and degradation in protein level, which can be totally reversed by PIO.</offsets><italic><offsets xml_i="6001" xml_f="6012" txt_i="1377" txt_f="1388"> Conclusion</offsets></italic><offsets xml_i="6021" xml_f="6074" txt_i="1388" txt_f="1441">. PIO treatment attenuated DES-induced PPAR loss, NF-</offsets><italic><offsets xml_i="6082" xml_f="6083" txt_i="1441" txt_f="1442">κ</offsets></italic><offsets xml_i="6092" xml_f="6229" txt_i="1442" txt_f="1579">B activation, and proinflammation, indicating that PIO may have a novel direct protective role in modulating proinflammation in DES era. </offsets></p></abstract></article-meta></front><body><sec id="sec1"><title><offsets xml_i="6295" xml_f="6310" txt_i="1587" txt_f="1602">1. Introduction</offsets></title><p><offsets xml_i="6321" xml_f="6735" txt_i="1603" txt_f="2017">Polymer-based drug-eluting (everolimus, zotarolimus, sirolimus, paclitaxel, etc.) stents (DES) have been known as a standard treatment for coronary artery diseases (CAD) undergoing percutaneous coronary angioplasties. Although DES has demonstrated efficacy and safety in clinical studies, human pathological data have raised concerns about the long-term healing and the potential for local inflammatory reactions [</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="6766" xml_f="6767" txt_i="2017" txt_f="2018">1</offsets></xref><offsets xml_i="6774" xml_f="6776" txt_i="2018" txt_f="2020">, </offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="6807" xml_f="6808" txt_i="2020" txt_f="2021">2</offsets></xref><offsets xml_i="6815" xml_f="7055" txt_i="2021" txt_f="2261">]. Also, it has been reported that DES induced hypersensitivity reactions with interacting lymphocytes, macrophages, multinucleated giant cells, and eosinophils and pervasive inflammation throughout the stented arterial segment by autopsy [</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="7086" xml_f="7087" txt_i="2261" txt_f="2262">3</offsets></xref><offsets xml_i="7094" xml_f="7267" txt_i="2262" txt_f="2435">]. DES-induced inflammatory reaction has been found as early as 30 days after implantation but progressed in frequency and severity through 90 to 180 days in porcine model [</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="7298" xml_f="7299" txt_i="2435" txt_f="2436">1</offsets></xref><offsets xml_i="7306" xml_f="7451" txt_i="2436" txt_f="2581">]. Furthermore, our previous studies found that DES implantation induced specific systematic inflammatory state, as evidenced by the enhanced NF-</offsets><italic><offsets xml_i="7459" xml_f="7460" txt_i="2581" txt_f="2582">κ</offsets></italic><offsets xml_i="7469" xml_f="7497" txt_i="2582" txt_f="2610">B activity, suppressed PPAR-</offsets><italic><offsets xml_i="7505" xml_f="7506" txt_i="2610" txt_f="2611">γ</offsets></italic><offsets xml_i="7515" xml_f="7644" txt_i="2611" txt_f="2740"> activity, and elevated plasma inflammatory factors, compared with no-stent implantation or bare metal stent (BMS) implantation [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="7675" xml_f="7676" txt_i="2740" txt_f="2741">4</offsets></xref><offsets xml_i="7683" xml_f="7685" txt_i="2741" txt_f="2743">, </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="7716" xml_f="7717" txt_i="2743" txt_f="2744">5</offsets></xref><offsets xml_i="7724" xml_f="7794" txt_i="2744" txt_f="2814">]. However, how to refine DES-induced proinflammation remains unknown.</offsets></p><p><offsets xml_i="7801" xml_f="7844" txt_i="2815" txt_f="2858">In vascular wall and atherosclerosis, PPAR-</offsets><italic><offsets xml_i="7852" xml_f="7853" txt_i="2858" txt_f="2859">γ</offsets></italic><offsets xml_i="7862" xml_f="7954" txt_i="2859" txt_f="2951"> is expressed in macrophages, T cells, endothelial cells, and vascular smooth muscle cells [</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="7985" xml_f="7986" txt_i="2951" txt_f="2952">6</offsets></xref><offsets xml_i="7993" xml_f="7995" txt_i="2952" txt_f="2954">, </offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="8026" xml_f="8027" txt_i="2954" txt_f="2955">7</offsets></xref><offsets xml_i="8034" xml_f="8139" txt_i="2955" txt_f="3060">]. Recent data have shown that synthetic antidiabetic thiazolidinediones (TZDs), which are known as PPAR-</offsets><italic><offsets xml_i="8147" xml_f="8148" txt_i="3060" txt_f="3061">γ</offsets></italic><offsets xml_i="8157" xml_f="8252" txt_i="3061" txt_f="3156"> activators, inhibit inflammatory cytokine production by cells of monocyte/macrophage lineage [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="8283" xml_f="8284" txt_i="3156" txt_f="3157">8</offsets></xref><offsets xml_i="8291" xml_f="8453" txt_i="3157" txt_f="3319">]. These activators inhibit gene expression in part by antagonizing the activities of transcription factors such as activator protein-1 (AP-1) and nuclear factor-</offsets><italic><offsets xml_i="8461" xml_f="8462" txt_i="3319" txt_f="3320">κ</offsets></italic><offsets xml_i="8471" xml_f="8477" txt_i="3320" txt_f="3326">B (NF-</offsets><italic><offsets xml_i="8485" xml_f="8486" txt_i="3326" txt_f="3327">κ</offsets></italic><offsets xml_i="8495" xml_f="8499" txt_i="3327" txt_f="3331">B) [</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="8530" xml_f="8531" txt_i="3331" txt_f="3332">9</offsets></xref><offsets xml_i="8538" xml_f="8540" txt_i="3332" txt_f="3334">, </offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="8572" xml_f="8574" txt_i="3334" txt_f="3336">10</offsets></xref><offsets xml_i="8581" xml_f="8662" txt_i="3336" txt_f="3417">]. Several animal studies have demonstrated the antiatherogenic effects of TZDs [</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="8694" xml_f="8696" txt_i="3417" txt_f="3419">11</offsets></xref><offsets xml_i="8703" xml_f="8705" txt_i="3419" txt_f="3421">, </offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="8737" xml_f="8739" txt_i="3421" txt_f="3423">12</offsets></xref><offsets xml_i="8746" xml_f="8992" txt_i="3423" txt_f="3669">]. Moreover, pioglitazone (PIO) significantly decreased the occurrence of all-cause mortality, nonfatal myocardial infarction, and stroke in diabetic populations in the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="9024" xml_f="9026" txt_i="3669" txt_f="3671">13</offsets></xref><offsets xml_i="9033" xml_f="9065" txt_i="3671" txt_f="3703">] and in a meta-analysis study [</offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="9097" xml_f="9099" txt_i="3703" txt_f="3705">14</offsets></xref><offsets xml_i="9106" xml_f="9283" txt_i="3705" txt_f="3882">]. However, a meta-analysis of rosiglitazone trials in diabetic patients showed that rosiglitazone was associated with increased myocardial infarction and cardiovascular death [</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="9315" xml_f="9317" txt_i="3882" txt_f="3884">15</offsets></xref><offsets xml_i="9324" xml_f="9458" txt_i="3884" txt_f="4018">]. In an animal study, PIO was found to increase macrophage apoptosis and plaque necrosis in advanced lesions in LDLr-deficient mice [</offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="9490" xml_f="9492" txt_i="4018" txt_f="4020">16</offsets></xref><offsets xml_i="9499" xml_f="9641" txt_i="4020" txt_f="4162">]. Another animal study found that pioglitazone could induce excessive hepatic triglyceride accumulation and increase the plasma cholesterol [</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="9673" xml_f="9675" txt_i="4162" txt_f="4164">17</offsets></xref><offsets xml_i="9682" xml_f="9684" txt_i="4164" txt_f="4166">].</offsets></p><p><offsets xml_i="9691" xml_f="10109" txt_i="4167" txt_f="4585">These conflicting and controversial findings highlight the uncertainty regarding the effectiveness of using TZDs to treat atherothrombotic disease. Whether PIO have atheroprotective effects in DES-treated CAD patients remains unknown. Here, we performed a random single-blind placebo controlled clinical study to investigate whether PIO have anti-inflammatory effects in DES-implanted coronary artery disease patients.</offsets></p></sec><sec id="sec2"><title><offsets xml_i="10141" xml_f="10151" txt_i="4587" txt_f="4597">2. Methods</offsets></title><sec id="sec2.1"><title><offsets xml_i="10183" xml_f="10213" txt_i="4598" txt_f="4628">2.1. Patients and Study Design</offsets></title><p><offsets xml_i="10224" xml_f="10479" txt_i="4629" txt_f="4884">All subjects were consecutively recruited from the First Affiliated Hospital of Xi'an Jiaotong University. 28 nondiabetic patients with coronary artery disease (CAD) and who underwent DES implantations were randomized into two groups: placebo group (Con, </offsets><italic><offsets xml_i="10487" xml_f="10488" txt_i="4884" txt_f="4885">n</offsets></italic><offsets xml_i="10497" xml_f="10533" txt_i="4885" txt_f="4921"> = 14) and pioglitazone group (PIO, </offsets><italic><offsets xml_i="10541" xml_f="10542" txt_i="4921" txt_f="4922">n</offsets></italic><offsets xml_i="10551" xml_f="11157" txt_i="4922" txt_f="5525"> = 14). The nondiabetic state was determined by a negative history of diabetes mellitus, no treatment with antidiabetic drugs, and assessment of fasting blood glucose and oral glucose tolerance test (OGTT). The diagnosis of CAD was in accorded with the WHO definition. The exclusion criteria included clinical evidence of acute inflammation, tumor and rheumatic condition checked by the elevated CRP and ESR, liver and renal diseases, severe heart failure (NYHA class ≥ II), ejection fraction (EF) &lt; 50%, contraindications to treatment with pioglitazone, and patients who were given immunosuppressants. </offsets><xref ref-type="table" rid="tab1"><offsets xml_i="11191" xml_f="11199" txt_i="5525" txt_f="5533"> Table 1</offsets></xref><offsets xml_i="11206" xml_f="11375" txt_i="5533" txt_f="5702"> summarized all subjects' demographic data. Study medication (30 mg/d) for 12 weeks was given in addition to optimal standard treatment, including aspirin, clopidogrel, </offsets><italic><offsets xml_i="11383" xml_f="11384" txt_i="5702" txt_f="5703">β</offsets></italic><offsets xml_i="11393" xml_f="11677" txt_i="5703" txt_f="5987"> receptor blockers, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), and statins. We followed up the patients twice after 4 and 12 weeks. Pioglitazone and placebo were provided by Zhongmei Huadong Pharmaceutical Co., Ltd. (Hangzhou, China).</offsets></p><p><offsets xml_i="11684" xml_f="12027" txt_i="5988" txt_f="6331">We obtained each patient's medical and family history and general information such as smoking and drinking by medical history interview. This study complies with the Declaration of Helsinki, and the research protocol has been approved by the Ethics Committee of Xi'an Jiaotong University. The informed consents were obtained from the subjects.</offsets></p></sec><sec id="sec2.2"><title><offsets xml_i="12061" xml_f="12098" txt_i="6333" txt_f="6370">2.2. Mononuclear Cell (MNC) Isolation</offsets></title><p><offsets xml_i="12109" xml_f="12437" txt_i="6371" txt_f="6699">Peripheral blood MNC samples before medication and at the end of the 12th week after DES stent implantation were collected. Peripheral blood MNC samples were isolated by Ficoll standard density gradient centrifugation. The upper layer containing MNC was harvested and washed with Hanks' balanced salt solution and then with PBS.</offsets></p></sec><sec id="sec2.3"><title><offsets xml_i="12471" xml_f="12526" txt_i="6701" txt_f="6756">2.3. Plasma Concentrations of Proinflammatory Cytokines</offsets></title><p><offsets xml_i="12537" xml_f="12610" txt_i="6757" txt_f="6830">The concentrations of plasma interleukin-6 (IL-6), tumor necrosis factor-</offsets><italic><offsets xml_i="12618" xml_f="12619" txt_i="6830" txt_f="6831">α</offsets></italic><offsets xml_i="12628" xml_f="12634" txt_i="6831" txt_f="6837"> (TNF-</offsets><italic><offsets xml_i="12642" xml_f="12643" txt_i="6837" txt_f="6838">α</offsets></italic><offsets xml_i="12652" xml_f="12751" txt_i="6838" txt_f="6937">), and matrix metalloproteinase-9 (MMP-9) were assayed by ELISA. ELISA was performed by adding 100 </offsets><italic><offsets xml_i="12759" xml_f="12760" txt_i="6937" txt_f="6938">μ</offsets></italic><offsets xml_i="12769" xml_f="12778" txt_i="6938" txt_f="6947">L or 200 </offsets><italic><offsets xml_i="12786" xml_f="12787" txt_i="6947" txt_f="6948">μ</offsets></italic><offsets xml_i="12796" xml_f="13056" txt_i="6948" txt_f="7208">L of each sample to wells in a 96-well plate of a commercially available ELISA Kit (ExCell, Shanghai) according to the manufacturer's instructions. High-sensitivity C-reactive protein (hs-CRP) assays were performed by our hospital's clinical centre laboratory.</offsets></p></sec><sec id="sec2.4"><title><offsets xml_i="13090" xml_f="13133" txt_i="7210" txt_f="7253">2.4. Total RNA Isolation and mRNA Detection</offsets></title><p><offsets xml_i="13144" xml_f="13342" txt_i="7254" txt_f="7452">Total RNA was extracted from MNC with the RNAfast kit (Fastgen) according to manufacturer's protocol, and real-time reverse transcription-polymerase chain reaction was performed as previous report [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="13373" xml_f="13374" txt_i="7452" txt_f="7453">4</offsets></xref><offsets xml_i="13381" xml_f="13383" txt_i="7453" txt_f="7455">].</offsets></p></sec><sec id="sec2.5"><title><offsets xml_i="13417" xml_f="13425" txt_i="7457" txt_f="7465">2.5. NF-</offsets><italic><offsets xml_i="13433" xml_f="13434" txt_i="7465" txt_f="7466">κ</offsets></italic><offsets xml_i="13443" xml_f="13454" txt_i="7466" txt_f="7477">B and PPAR-</offsets><italic><offsets xml_i="13462" xml_f="13463" txt_i="7477" txt_f="7478">γ</offsets></italic><offsets xml_i="13472" xml_f="13493" txt_i="7478" txt_f="7499"> DNA Binding Activity</offsets></title><p><offsets xml_i="13504" xml_f="13598" txt_i="7500" txt_f="7594">Nuclear proteins were extracted according to the manufacturer's instructions (Pierce). The NF-</offsets><italic><offsets xml_i="13606" xml_f="13607" txt_i="7594" txt_f="7595">κ</offsets></italic><offsets xml_i="13616" xml_f="13627" txt_i="7595" txt_f="7606">B and PPAR-</offsets><italic><offsets xml_i="13635" xml_f="13636" txt_i="7606" txt_f="7607">γ</offsets></italic><offsets xml_i="13645" xml_f="13689" txt_i="7607" txt_f="7651"> DNA binding activity were measured with NF-</offsets><italic><offsets xml_i="13697" xml_f="13698" txt_i="7651" txt_f="7652">κ</offsets></italic><offsets xml_i="13707" xml_f="13726" txt_i="7652" txt_f="7671">B p65/p50 and PPAR-</offsets><italic><offsets xml_i="13734" xml_f="13735" txt_i="7671" txt_f="7672">γ</offsets></italic><offsets xml_i="13744" xml_f="13829" txt_i="7672" txt_f="7757"> transcription factor assay kit (Abcam) according to the manufacturers' instructions.</offsets></p></sec><sec id="sec2.6"><title><offsets xml_i="13863" xml_f="13884" txt_i="7759" txt_f="7780">2.6. Western Blotting</offsets></title><p><offsets xml_i="13895" xml_f="14093" txt_i="7781" txt_f="7979">Polyclonal or monoclonal antibodies (Santa Cruz Biotechnology) were used. Densitometry was performed with the Bio-Rad molecular analyst software, and all values were corrected by loading with Gapdh.</offsets></p></sec><sec id="sec2.7"><title><offsets xml_i="14127" xml_f="14152" txt_i="7981" txt_f="8006">2.7. Statistical Analysis</offsets></title><p><offsets xml_i="14163" xml_f="14244" txt_i="8007" txt_f="8088">Discrete variables were expressed as numbers and percentages and compared by the </offsets><italic><offsets xml_i="14252" xml_f="14253" txt_i="8088" txt_f="8089">χ</offsets></italic><offsets xml_i="14262" xml_f="14263" txt_i="8089" txt_f="8090">
</offsets><sup><offsets xml_i="14268" xml_f="14269" txt_i="8090" txt_f="8091">2</offsets></sup><offsets xml_i="14275" xml_f="14446" txt_i="8091" txt_f="8262"> test. Summary values are expressed as mean ± SE. Skewed data were reported as median (interquartile range). Analysis of the changes from baseline was performed by paired </offsets><italic><offsets xml_i="14454" xml_f="14455" txt_i="8262" txt_f="8263">t</offsets></italic><offsets xml_i="14464" xml_f="14623" txt_i="8263" txt_f="8422">-test. Holm-Sidak two-way repeated-measures ANOVA (TWRMANOVA) method was used for all multiple comparisons between the Con and PIO groups as previous reports [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="14654" xml_f="14655" txt_i="8422" txt_f="8423">4</offsets></xref><offsets xml_i="14662" xml_f="14664" txt_i="8423" txt_f="8425">, </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="14695" xml_f="14696" txt_i="8425" txt_f="8426">5</offsets></xref><offsets xml_i="14703" xml_f="14754" txt_i="8426" txt_f="8477">]. Statistical significance was assumed at the 5%  </offsets><italic><offsets xml_i="14762" xml_f="14763" txt_i="8477" txt_f="8478">α</offsets></italic><offsets xml_i="14772" xml_f="14786" txt_i="8478" txt_f="8492">-error level (</offsets><italic><offsets xml_i="14794" xml_f="14795" txt_i="8492" txt_f="8493">P</offsets></italic><offsets xml_i="14804" xml_f="14816" txt_i="8493" txt_f="8502"> &lt; 0.05).</offsets></p></sec></sec><sec id="sec3"><title><offsets xml_i="14854" xml_f="14864" txt_i="8505" txt_f="8515">3. Results</offsets></title><sec id="sec3.1"><title><offsets xml_i="14896" xml_f="14922" txt_i="8516" txt_f="8542">3.1. General Clinical Data</offsets></title><p><offsets xml_i="14933" xml_f="15068" txt_i="8543" txt_f="8678">All 28 patients fulfilled the 12 weeks' follow-up without any drug related side effects. The characteristics of patients were shown in </offsets><xref ref-type="table" rid="tab1"><offsets xml_i="15102" xml_f="15109" txt_i="8678" txt_f="8685">Table 1</offsets></xref><offsets xml_i="15116" xml_f="15453" txt_i="8685" txt_f="9022">. There were no differences between the PIO and placebo groups with respect to baseline characteristics. After 12 weeks of treatment, there was no significant change in body mass index (BMI), weight, waist to hip ratio, blood pressure (SBP or DBP), fasting glucose and insulin, NT-pro BNP, and EF of the two groups compared to baseline (</offsets><xref ref-type="table" rid="tab2"><offsets xml_i="15487" xml_f="15494" txt_i="9022" txt_f="9029">Table 2</offsets></xref><offsets xml_i="15501" xml_f="15857" txt_i="9029" txt_f="9385">). Considering the unchanged BMI, weight, waist to hip ratio, NT-pro BNP, and EF between two groups, there was no evidence of PIO increasing the occurrence of heart failure in the present study. Total cholesterol, triglycerides, and LDL were reduced significantly after medication; however, no disparities of the reduction between two groups were observed.</offsets></p></sec><sec id="sec3.2"><title><offsets xml_i="15891" xml_f="15971" txt_i="9387" txt_f="9467">3.2. Pioglitazone Reduced the Plasma Concentrations of Proinflammatory Cytokines</offsets></title><p><offsets xml_i="15982" xml_f="16039" txt_i="9468" txt_f="9525">In the control group, plasma concentrations of IL-6, TNF-</offsets><italic><offsets xml_i="16047" xml_f="16048" txt_i="9525" txt_f="9526">α</offsets></italic><offsets xml_i="16057" xml_f="16187" txt_i="9526" txt_f="9656">, and MMP-9 were increased by 138 ± 16%, 136 ± 15%, and 110 ± 7%, respectively, compared with the baseline level at 12 wk (paired </offsets><italic><offsets xml_i="16195" xml_f="16196" txt_i="9656" txt_f="9657">t</offsets></italic><offsets xml_i="16205" xml_f="16212" txt_i="9657" txt_f="9664">-test, </offsets><italic><offsets xml_i="16220" xml_f="16221" txt_i="9664" txt_f="9665">P</offsets></italic><offsets xml_i="16230" xml_f="16273" txt_i="9665" txt_f="9708"> = 0.033, 0.041, and 0.142, resp., Figures </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="16305" xml_f="16309" txt_i="9708" txt_f="9712">1(a)</offsets></xref><offsets xml_i="16316" xml_f="16317" txt_i="9712" txt_f="9713">–</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="16349" xml_f="16353" txt_i="9713" txt_f="9717">1(c)</offsets></xref><offsets xml_i="16360" xml_f="16473" txt_i="9717" txt_f="9830">), indicating DES-related proinflammatory status. In the PIO treatment group, plasma concentrations of IL-6, TNF-</offsets><italic><offsets xml_i="16481" xml_f="16482" txt_i="9830" txt_f="9831">α</offsets></italic><offsets xml_i="16491" xml_f="16602" txt_i="9831" txt_f="9942">, and MMP-9 were decreased by 89 ± 8%, 64 ± 16%, and 86 ± 6% compared with the baseline level at 12 wk (paired </offsets><italic><offsets xml_i="16610" xml_f="16611" txt_i="9942" txt_f="9943">t</offsets></italic><offsets xml_i="16620" xml_f="16627" txt_i="9943" txt_f="9950">-test, </offsets><italic><offsets xml_i="16635" xml_f="16636" txt_i="9950" txt_f="9951">P</offsets></italic><offsets xml_i="16645" xml_f="16688" txt_i="9951" txt_f="9994"> = 0.204, 0.041, and 0.037, resp., Figures </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="16720" xml_f="16724" txt_i="9994" txt_f="9998">1(a)</offsets></xref><offsets xml_i="16731" xml_f="16732" txt_i="9998" txt_f="9999">–</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="16764" xml_f="16768" txt_i="9999" txt_f="10003">1(c)</offsets></xref><offsets xml_i="16775" xml_f="16866" txt_i="10003" txt_f="10094">). Compared to the control group, PIO treatment significantly reduced the plasma IL-6, TNF-</offsets><italic><offsets xml_i="16874" xml_f="16875" txt_i="10094" txt_f="10095">α</offsets></italic><offsets xml_i="16884" xml_f="16923" txt_i="10095" txt_f="10134">, and MMP-9 concentrations (TWRMANOVA, </offsets><italic><offsets xml_i="16931" xml_f="16932" txt_i="10134" txt_f="10135">P</offsets></italic><offsets xml_i="16941" xml_f="17116" txt_i="10135" txt_f="10310"> = 0.011, 0.008, and 0.012, resp.). Moreover, hs-CRP in both Con and PIO treatment groups were decreased significantly and more drastically in PIO treatment group (TWRMANOVA, </offsets><italic><offsets xml_i="17124" xml_f="17125" txt_i="10310" txt_f="10311">P</offsets></italic><offsets xml_i="17134" xml_f="17144" txt_i="10311" txt_f="10321"> = 0.035, </offsets><xref ref-type="table" rid="tab2"><offsets xml_i="17178" xml_f="17185" txt_i="10321" txt_f="10328">Table 2</offsets></xref><offsets xml_i="17192" xml_f="17194" txt_i="10328" txt_f="10330">).</offsets></p></sec><sec id="sec3.3"><title><offsets xml_i="17228" xml_f="17309" txt_i="10332" txt_f="10413">3.3. Pioglitazone Downregulated the Expressions of Proinflammatory Factors in MNC</offsets></title><p><offsets xml_i="17320" xml_f="17629" txt_i="10414" txt_f="10723">To examine whether the reduction of plasma proinflammatory cytokines by PIO treatment might be associated with downregulation of the mRNA expressions of proinflammatory cytokines in MNC, quantitative real-time PCR was used to calculate the mRNA expression. In the Con group, the mRNA expressions of IL-6, TNF-</offsets><italic><offsets xml_i="17637" xml_f="17638" txt_i="10723" txt_f="10724">α</offsets></italic><offsets xml_i="17647" xml_f="17732" txt_i="10724" txt_f="10809">, and MMP-9 at 12 weeks' follow-up were increased compared with the baseline (paired </offsets><italic><offsets xml_i="17740" xml_f="17741" txt_i="10809" txt_f="10810">t</offsets></italic><offsets xml_i="17750" xml_f="17757" txt_i="10810" txt_f="10817">-test, </offsets><italic><offsets xml_i="17765" xml_f="17766" txt_i="10817" txt_f="10818">P</offsets></italic><offsets xml_i="17775" xml_f="17818" txt_i="10818" txt_f="10861"> = 0.009, 0.025, and 0.105, resp., Figures </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="17850" xml_f="17854" txt_i="10861" txt_f="10865">2(a)</offsets></xref><offsets xml_i="17861" xml_f="17862" txt_i="10865" txt_f="10866">–</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="17894" xml_f="17898" txt_i="10866" txt_f="10870">2(c)</offsets></xref><offsets xml_i="17905" xml_f="18007" txt_i="10870" txt_f="10972">). Compared with the Con group, PIO treatment significantly reduced the mRNA expressions of IL-6, TNF-</offsets><italic><offsets xml_i="18015" xml_f="18016" txt_i="10972" txt_f="10973">α</offsets></italic><offsets xml_i="18025" xml_f="18049" txt_i="10973" txt_f="10997">, and MMP-9 (TWRMANOVA, </offsets><italic><offsets xml_i="18057" xml_f="18058" txt_i="10997" txt_f="10998">P</offsets></italic><offsets xml_i="18067" xml_f="18109" txt_i="10998" txt_f="11040"> = 0.031, 0.012, and 0.007 resp., Figures </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="18141" xml_f="18145" txt_i="11040" txt_f="11044">2(a)</offsets></xref><offsets xml_i="18152" xml_f="18153" txt_i="11044" txt_f="11045">–</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="18185" xml_f="18189" txt_i="11045" txt_f="11049">2(c)</offsets></xref><offsets xml_i="18196" xml_f="18283" txt_i="11049" txt_f="11136">), indicating that PIO attenuate DES-induced proinflammatory factors expression in MNC.</offsets></p></sec><sec id="sec3.4"><title><offsets xml_i="18317" xml_f="18364" txt_i="11138" txt_f="11185">3.4. Pioglitazone Regulated the DES-Induced NF-</offsets><italic><offsets xml_i="18372" xml_f="18373" txt_i="11185" txt_f="11186">κ</offsets></italic><offsets xml_i="18382" xml_f="18389" txt_i="11186" txt_f="11193">B/PPAR-</offsets><italic><offsets xml_i="18397" xml_f="18398" txt_i="11193" txt_f="11194">γ</offsets></italic><offsets xml_i="18407" xml_f="18425" txt_i="11194" txt_f="11212"> Imbalance In Vivo</offsets></title><p><offsets xml_i="18436" xml_f="18528" txt_i="11213" txt_f="11305">To evaluate whether pioglitazone interacts with the proinflammatory transcription factor NF-</offsets><italic><offsets xml_i="18536" xml_f="18537" txt_i="11305" txt_f="11306">κ</offsets></italic><offsets xml_i="18546" xml_f="18583" txt_i="11306" txt_f="11343">B in MNC, we measured the nuclear NF-</offsets><italic><offsets xml_i="18591" xml_f="18592" txt_i="11343" txt_f="11344">κ</offsets></italic><offsets xml_i="18601" xml_f="18633" txt_i="11344" txt_f="11376">B DNA binding activity in MNCs (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="18665" xml_f="18676" txt_i="11376" txt_f="11387">Figure 2(a)</offsets></xref><offsets xml_i="18683" xml_f="18701" txt_i="11387" txt_f="11405">). As depicted in </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="18733" xml_f="18744" txt_i="11405" txt_f="11416">Figure 2(d)</offsets></xref><offsets xml_i="18751" xml_f="18797" txt_i="11416" txt_f="11462">, DES enhanced the DNA binding activity of NF-</offsets><italic><offsets xml_i="18805" xml_f="18806" txt_i="11462" txt_f="11463">κ</offsets></italic><offsets xml_i="18815" xml_f="18818" txt_i="11463" txt_f="11466">B (</offsets><italic><offsets xml_i="18826" xml_f="18827" txt_i="11466" txt_f="11467">P</offsets></italic><offsets xml_i="18836" xml_f="18888" txt_i="11467" txt_f="11519"> = 0.023), which were attenuated by PIO (TWRMANOVA, </offsets><italic><offsets xml_i="18896" xml_f="18897" txt_i="11519" txt_f="11520">P</offsets></italic><offsets xml_i="18906" xml_f="18916" txt_i="11520" txt_f="11530"> = 0.017).</offsets></p><p><offsets xml_i="18923" xml_f="18998" txt_i="11531" txt_f="11606">Next, we detected the expressions of the p50 subunit and p65 subunit of NF-</offsets><italic><offsets xml_i="19006" xml_f="19007" txt_i="11606" txt_f="11607">κ</offsets></italic><offsets xml_i="19016" xml_f="19039" txt_i="11607" txt_f="11630">B in MNCs. As shown in </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="19071" xml_f="19082" txt_i="11630" txt_f="11641">Figure 2(e)</offsets></xref><offsets xml_i="19089" xml_f="19166" txt_i="11641" txt_f="11718">, PIO treatment significantly reduced DES-induced p50 expression (TWRMANOVA, </offsets><italic><offsets xml_i="19174" xml_f="19175" txt_i="11718" txt_f="11719">P</offsets></italic><offsets xml_i="19184" xml_f="19227" txt_i="11719" txt_f="11762"> = 0.017) but did not alter p65 expression.</offsets></p><p><offsets xml_i="19234" xml_f="19263" txt_i="11763" txt_f="11792">Moreover, we found that PPAR-</offsets><italic><offsets xml_i="19271" xml_f="19272" txt_i="11792" txt_f="11793">γ</offsets></italic><offsets xml_i="19281" xml_f="19328" txt_i="11793" txt_f="11840"> were dramatically decreased in the DES group (</offsets><italic><offsets xml_i="19336" xml_f="19337" txt_i="11840" txt_f="11841">P</offsets></italic><offsets xml_i="19346" xml_f="19356" txt_i="11841" txt_f="11851"> = 0.038, </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="19388" xml_f="19399" txt_i="11851" txt_f="11862">Figure 3(a)</offsets></xref><offsets xml_i="19406" xml_f="19458" txt_i="11862" txt_f="11914">), which were reversed by PIO treatment (TWRMANOVA, </offsets><italic><offsets xml_i="19466" xml_f="19467" txt_i="11914" txt_f="11915">P</offsets></italic><offsets xml_i="19476" xml_f="19486" txt_i="11915" txt_f="11925"> = 0.027, </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="19518" xml_f="19529" txt_i="11925" txt_f="11936">Figure 3(a)</offsets></xref><offsets xml_i="19536" xml_f="19597" txt_i="11936" txt_f="11997">), suggesting that pioglitazone regulated the DES-induced NF-</offsets><italic><offsets xml_i="19605" xml_f="19606" txt_i="11997" txt_f="11998">κ</offsets></italic><offsets xml_i="19615" xml_f="19622" txt_i="11998" txt_f="12005">B/PPAR-</offsets><italic><offsets xml_i="19630" xml_f="19631" txt_i="12005" txt_f="12006">γ</offsets></italic><offsets xml_i="19640" xml_f="19659" txt_i="12006" txt_f="12025"> imbalance in vivo.</offsets></p></sec><sec id="sec3.5"><title><offsets xml_i="19693" xml_f="19742" txt_i="12027" txt_f="12076">3.5. Pioglitazone Regulated the DES-Induced PPAR-</offsets><italic><offsets xml_i="19750" xml_f="19751" txt_i="12076" txt_f="12077">γ</offsets></italic><offsets xml_i="19760" xml_f="19791" txt_i="12077" txt_f="12108"> Ubiquitination and Degradation</offsets></title><p><offsets xml_i="19802" xml_f="19864" txt_i="12109" txt_f="12171">To refine the changes of protein and mRNA expressions of PPAR-</offsets><italic><offsets xml_i="19872" xml_f="19873" txt_i="12171" txt_f="12172">γ</offsets></italic><offsets xml_i="19882" xml_f="19956" txt_i="12172" txt_f="12246">, Western blot and quantitative real-time PCR were performed. As shown in </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="19988" xml_f="19999" txt_i="12246" txt_f="12257">Figure 3(b)</offsets></xref><offsets xml_i="20006" xml_f="20036" txt_i="12257" txt_f="12287">, DES markedly decreased PPAR-</offsets><italic><offsets xml_i="20044" xml_f="20045" txt_i="12287" txt_f="12288">γ</offsets></italic><offsets xml_i="20054" xml_f="20118" txt_i="12288" txt_f="12352"> protein level, which were blocked by PIO treatment (TWRMANOVA, </offsets><italic><offsets xml_i="20126" xml_f="20127" txt_i="12352" txt_f="12353">P</offsets></italic><offsets xml_i="20136" xml_f="20146" txt_i="12353" txt_f="12363"> = 0.031, </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="20178" xml_f="20189" txt_i="12363" txt_f="12374">Figure 3(b)</offsets></xref><offsets xml_i="20196" xml_f="20241" txt_i="12374" txt_f="12419">). We also found that PIO did not alter PPAR-</offsets><italic><offsets xml_i="20249" xml_f="20250" txt_i="12419" txt_f="12420">γ</offsets></italic><offsets xml_i="20259" xml_f="20393" txt_i="12420" txt_f="12554"> mRNA expression, suggesting that PIO may regulate the protein stability in vivo. Furthermore, we detected the ubiquitination of PPAR-</offsets><italic><offsets xml_i="20401" xml_f="20402" txt_i="12554" txt_f="12555">γ</offsets></italic><offsets xml_i="20411" xml_f="20444" txt_i="12555" txt_f="12588"> by Western blot. As depicted in </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="20476" xml_f="20487" txt_i="12588" txt_f="12599">Figure 3(d)</offsets></xref><offsets xml_i="20494" xml_f="20527" txt_i="12599" txt_f="12632">, DES significantly induced PPAR-</offsets><italic><offsets xml_i="20535" xml_f="20536" txt_i="12632" txt_f="12633">γ</offsets></italic><offsets xml_i="20545" xml_f="20562" txt_i="12633" txt_f="12650"> ubiquitination (</offsets><italic><offsets xml_i="20570" xml_f="20571" txt_i="12650" txt_f="12651">P</offsets></italic><offsets xml_i="20580" xml_f="20675" txt_i="12651" txt_f="12746"> = 0.043), which was blocked by PIO, implying that pioglitazone regulated the DES-induced PPAR-</offsets><italic><offsets xml_i="20683" xml_f="20684" txt_i="12746" txt_f="12747">γ</offsets></italic><offsets xml_i="20693" xml_f="20733" txt_i="12747" txt_f="12787"> ubiquitination and degradation in vivo.</offsets></p></sec></sec><sec id="sec4"><title><offsets xml_i="20771" xml_f="20784" txt_i="12790" txt_f="12803">4. Discussion</offsets></title><p><offsets xml_i="20795" xml_f="21065" txt_i="12804" txt_f="13074">The present study clearly showed that the circulating inflammatory responses were increased after the implantation of DES in the CAD patients treated with optimal drug combinations, which were blocked by addition of oral pioglitazone. PIO sequentially acts through PPAR-</offsets><italic><offsets xml_i="21073" xml_f="21074" txt_i="13074" txt_f="13075">γ</offsets></italic><offsets xml_i="21083" xml_f="21099" txt_i="13075" txt_f="13091"> activation, NF-</offsets><italic><offsets xml_i="21107" xml_f="21108" txt_i="13091" txt_f="13092">κ</offsets></italic><offsets xml_i="21117" xml_f="21424" txt_i="13092" txt_f="13399">B blockade, and inhibition of inflammatory cytokine expressions. These findings suggested that PIO may have a novel direct protective role in modulating the proinflammatory responses after coronary DES implantation in CAD patients, thus providing further optimizations of the drug therapy in those patients.</offsets></p><p><offsets xml_i="21431" xml_f="21565" txt_i="13400" txt_f="13534">Vascular inflammation is recognized as the foundation mechanism of atherosclerosis, and proinflammatory mediators including IL-6, TNF-</offsets><italic><offsets xml_i="21573" xml_f="21574" txt_i="13534" txt_f="13535">α</offsets></italic><offsets xml_i="21583" xml_f="21635" txt_i="13535" txt_f="13587">, and MMP-9 play a pivotal role in atherosclerosis [</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="21667" xml_f="21669" txt_i="13587" txt_f="13589">18</offsets></xref><offsets xml_i="21676" xml_f="21692" txt_i="13589" txt_f="13605">]. IL-6 and TNF-</offsets><italic><offsets xml_i="21700" xml_f="21701" txt_i="13605" txt_f="13606">α</offsets></italic><offsets xml_i="21710" xml_f="21792" txt_i="13606" txt_f="13688"> are classic proinflammatory cytokines, which play key roles in vascular disease [</offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="21824" xml_f="21826" txt_i="13688" txt_f="13690">19</offsets></xref><offsets xml_i="21833" xml_f="22011" txt_i="13690" txt_f="13868">]. Excessive degradation and remodeling of the extracellular matrix, a promoter of the instability of plaques, are the major effect of matrix metalloproteinases (such as MMP-9) [</offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="22043" xml_f="22045" txt_i="13868" txt_f="13870">20</offsets></xref><offsets xml_i="22052" xml_f="22141" txt_i="13870" txt_f="13959">]. DESs left target vascular intima partially unendothelialized for a sustaining period [</offsets><xref rid="B21" ref-type="bibr"><offsets xml_i="22173" xml_f="22175" txt_i="13959" txt_f="13961">21</offsets></xref><offsets xml_i="22182" xml_f="22352" txt_i="13961" txt_f="14131">], resulting in intensely inflammation-arousing vessel segments, which may facilitate the release of multiple proinflammatory factors into serum and then proinflammation.</offsets></p><p><offsets xml_i="22359" xml_f="22617" txt_i="14132" txt_f="14390">It has been reported that PIO may exhibit several antiatherosclerotic effects through multiple mechanisms, including modulation of blood pressure, lipid concentrations, matrix remodeling activation of matrix proteases, and finally induction of inflammation [</offsets><xref rid="B22" ref-type="bibr"><offsets xml_i="22649" xml_f="22651" txt_i="14390" txt_f="14392">22</offsets></xref><offsets xml_i="22658" xml_f="23258" txt_i="14392" txt_f="14992">]. In the present study, we failed to observe a reduction of blood pressure, blood glucose, insulin, or HbA1c levels in both groups. Firstly, the unchangeable blood pressure and other metabolic parameters may be explained as follows: first, the blood pressure of all subjects was already under control by optimal treatment and the patients included in this study were all nondiabetics. Moreover, it has been reported that PIO treatment had no significant effect on the level of total cholesterol, LDL, and HDL. The improved lipid profile and hs-CRP are mainly attributed to the standard drug therapy.</offsets></p><p><offsets xml_i="23265" xml_f="23322" txt_i="14993" txt_f="15050">Herein, we found a novel mechanism that PIO enhance PPAR-</offsets><italic><offsets xml_i="23330" xml_f="23331" txt_i="15050" txt_f="15051">γ</offsets></italic><offsets xml_i="23340" xml_f="23464" txt_i="15051" txt_f="15175"> binding activity though inhibiting its ubiquitination and degradation, which may play a key role in PPAR function in vivo [</offsets><xref rid="B23" ref-type="bibr"><offsets xml_i="23496" xml_f="23498" txt_i="15175" txt_f="15177">23</offsets></xref><offsets xml_i="23505" xml_f="23507" txt_i="15177" txt_f="15179">].</offsets></p><p><offsets xml_i="23514" xml_f="23707" txt_i="15180" txt_f="15373">Taken together, our study demonstrated that PIO treatment attenuated the proinflammatory state in circulating MNCs; and our results suggest that PIO treatment may sequentially act through PPAR-</offsets><italic><offsets xml_i="23715" xml_f="23716" txt_i="15373" txt_f="15374">γ</offsets></italic><offsets xml_i="23725" xml_f="23753" txt_i="15374" txt_f="15402"> activation, blocking of NF-</offsets><italic><offsets xml_i="23761" xml_f="23762" txt_i="15402" txt_f="15403">κ</offsets></italic><offsets xml_i="23771" xml_f="24054" txt_i="15403" txt_f="15686">B activation, and inhibition of inflammatory cytokine expressions. These findings suggest that PIO may have a novel direct atheroprotective role by modulating the local and circulating proinflammatory responses in patients with coronary polymer-based drug-eluting stent implantation.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Professor Nanping Wang and Yue Wu for their thoughtful suggestions. This study was supported in part by Natural Science Foundation of China (81500219, 30570732, and 30871043).</p></ack><sec><title>Competing Interests</title><p>The authors declare no competing interests.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>G. J.</given-names></name><name><surname>Nakazawa</surname><given-names>G.</given-names></name><name><surname>Schwartz</surname><given-names>R. S.</given-names></name><etal></etal></person-group><article-title>Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries</article-title><source><italic>Circulation</italic></source><year>2009</year><volume>120</volume><issue>2</issue><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.107.730010</pub-id><pub-id pub-id-type="other">2-s2.0-67651119696</pub-id><pub-id pub-id-type="pmid">19564562</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>A. V.</given-names></name><name><surname>Nakazawa</surname><given-names>G.</given-names></name><name><surname>Joner</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Vascular responses to drug eluting stents: importance of delayed healing</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2007</year><volume>27</volume><issue>7</issue><fpage>1500</fpage><lpage>1510</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.107.144220</pub-id><pub-id pub-id-type="other">2-s2.0-34250835092</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joner</surname><given-names>M.</given-names></name><name><surname>Morimoto</surname><given-names>K.</given-names></name><name><surname>Kasukawa</surname><given-names>H.</given-names></name><etal></etal></person-group><article-title>Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2008</year><volume>28</volume><issue>11</issue><fpage>1960</fpage><lpage>1966</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.108.170662</pub-id><pub-id pub-id-type="other">2-s2.0-55449121133</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhuo</surname><given-names>X.-Z.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><etal></etal></person-group><article-title>Drug-eluting stent, but not bare metal stent, accentuates the systematic inflammatory response in patients</article-title><source><italic>Cardiology</italic></source><year>2014</year><volume>128</volume><issue>3</issue><fpage>259</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1159/000358508</pub-id><pub-id pub-id-type="other">2-s2.0-84900879534</pub-id><pub-id pub-id-type="pmid">24852180</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Zhuo</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Yuan</surname><given-names>Z.</given-names></name></person-group><article-title>The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent</article-title><source><italic>Atherosclerosis</italic></source><year>2011</year><volume>215</volume><issue>1</issue><fpage>170</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2010.12.007</pub-id><pub-id pub-id-type="other">2-s2.0-79952107428</pub-id><pub-id pub-id-type="pmid">21227422</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W.-S.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptors and the heart: lessons from the past and future directions</article-title><source><italic>PPAR Research</italic></source><year>2015</year><volume>2015</volume><fpage>18</fpage><pub-id pub-id-type="publisher-id">271983</pub-id><pub-id pub-id-type="doi">10.1155/2015/271983</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>R. B.</given-names></name><name><surname>Bishop-Bailey</surname><given-names>D.</given-names></name><name><surname>Estrada-Hernandez</surname><given-names>T.</given-names></name><name><surname>Hla</surname><given-names>T.</given-names></name><name><surname>Puddington</surname><given-names>L.</given-names></name><name><surname>Padula</surname><given-names>S. J.</given-names></name></person-group><article-title>The nuclear receptor PPAR<italic>γ</italic> and immunoregulation: PPAR<italic>γ</italic> mediates inhibition of helper T cell responses</article-title><source><italic>Journal of Immunology</italic></source><year>2000</year><volume>164</volume><issue>3</issue><fpage>1364</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.3.1364</pub-id><pub-id pub-id-type="other">2-s2.0-0034141545</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuzzocrea</surname><given-names>S.</given-names></name><name><surname>Pisano</surname><given-names>B.</given-names></name><name><surname>Dugo</surname><given-names>L.</given-names></name><etal></etal></person-group><article-title>Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-<italic>γ</italic>, reduces acute inflammation</article-title><source><italic>European Journal of Pharmacology</italic></source><year>2004</year><volume>483</volume><issue>1</issue><fpage>79</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2003.10.056</pub-id><pub-id pub-id-type="other">2-s2.0-0347357686</pub-id><pub-id pub-id-type="pmid">14709329</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricote</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Fajas</surname><given-names>L.</given-names></name><etal></etal></person-group><article-title>Expression of the peroxisome proliferator-activated receptor <italic>γ</italic> (PPAR<italic>γ</italic>) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1998</year><volume>95</volume><issue>13</issue><fpage>7614</fpage><lpage>7619</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.13.7614</pub-id><pub-id pub-id-type="other">2-s2.0-0032560545</pub-id><pub-id pub-id-type="pmid">9636198</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>N.</given-names></name><name><surname>Schönbeck</surname><given-names>U.</given-names></name><name><surname>Lazar</surname><given-names>M. A.</given-names></name><name><surname>Libby</surname><given-names>P.</given-names></name><name><surname>Plutzky</surname><given-names>J.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells</article-title><source><italic>Circulation Research</italic></source><year>1998</year><volume>83</volume><issue>11</issue><fpage>1097</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1161/01.RES.83.11.1097</pub-id><pub-id pub-id-type="other">2-s2.0-0344333464</pub-id><pub-id pub-id-type="pmid">9831704</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Ishibashi</surname><given-names>S.</given-names></name><name><surname>Perrey</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2001</year><volume>21</volume><issue>3</issue><fpage>372</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1161/01.atv.21.3.372</pub-id><pub-id pub-id-type="other">2-s2.0-0035097590</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>A. R.</given-names></name><name><surname>Meehan</surname><given-names>W. P.</given-names></name><name><surname>Kintscher</surname><given-names>U.</given-names></name><etal></etal></person-group><article-title>Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2001</year><volume>21</volume><issue>3</issue><fpage>365</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1161/01.atv.21.3.365</pub-id><pub-id pub-id-type="other">2-s2.0-0035093258</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dormandy</surname><given-names>J. A.</given-names></name><name><surname>Charbonnel</surname><given-names>B.</given-names></name><name><surname>Eckland</surname><given-names>D. J. A.</given-names></name><etal></etal></person-group><article-title>Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial</article-title><source><italic>The Lancet</italic></source><year>2005</year><volume>366</volume><issue>9493</issue><fpage>1279</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(05)67528-9</pub-id><pub-id pub-id-type="other">2-s2.0-26244453309</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lincoff</surname><given-names>A. M.</given-names></name><name><surname>Wolski</surname><given-names>K.</given-names></name><name><surname>Nicholls</surname><given-names>S. J.</given-names></name><name><surname>Nissen</surname><given-names>S. E.</given-names></name></person-group><article-title>Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials</article-title><source><italic>The Journal of the American Medical Association</italic></source><year>2007</year><volume>298</volume><issue>10</issue><fpage>1180</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1001/jama.298.10.1180</pub-id><pub-id pub-id-type="other">2-s2.0-34548590934</pub-id><pub-id pub-id-type="pmid">17848652</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>S. E.</given-names></name><name><surname>Wolski</surname><given-names>K.</given-names></name></person-group><article-title>Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2007</year><volume>356</volume><issue>24</issue><fpage>2457</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.1056/nejmoa072761</pub-id><pub-id pub-id-type="other">2-s2.0-34250212715</pub-id><pub-id pub-id-type="pmid">17517853</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorp</surname><given-names>E.</given-names></name><name><surname>Kuriakose</surname><given-names>G.</given-names></name><name><surname>Shah</surname><given-names>Y. M.</given-names></name><name><surname>Gonzalez</surname><given-names>F. J.</given-names></name><name><surname>Tabas</surname><given-names>I.</given-names></name></person-group><article-title>Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice</article-title><source><italic>Circulation</italic></source><year>2007</year><volume>116</volume><issue>19</issue><fpage>2182</fpage><lpage>2190</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.698852</pub-id><pub-id pub-id-type="other">2-s2.0-35848933241</pub-id><pub-id pub-id-type="pmid">17967777</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Huan</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>S.-J.</given-names></name><name><surname>Jia</surname><given-names>C.-M.</given-names></name><name><surname>Shen</surname><given-names>Z.-F.</given-names></name></person-group><article-title>Effects and potential mechanisms of pioglitazone on lipid metabolism in obese diabetic KKAy mice</article-title><source><italic>PPAR Research</italic></source><year>2014</year><volume>2014</volume><fpage>13</fpage><pub-id pub-id-type="publisher-id">538183</pub-id><pub-id pub-id-type="doi">10.1155/2014/538183</pub-id><pub-id pub-id-type="other">2-s2.0-84899494559</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nylænde</surname><given-names>M.</given-names></name><name><surname>Kroese</surname><given-names>A.</given-names></name><name><surname>Stranden</surname><given-names>E.</given-names></name><etal></etal></person-group><article-title>Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease</article-title><source><italic>Vascular Medicine</italic></source><year>2006</year><volume>11</volume><issue>1</issue><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1191/1358863x06vm662oa</pub-id><pub-id pub-id-type="other">2-s2.0-33645729951</pub-id><pub-id pub-id-type="pmid">16669409</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>N.</given-names></name><name><surname>Wöhrle</surname><given-names>J.</given-names></name><name><surname>Nusser</surname><given-names>T.</given-names></name><etal></etal></person-group><article-title>Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients</article-title><source><italic>Circulation</italic></source><year>2005</year><volume>112</volume><issue>18</issue><fpage>2792</fpage><lpage>2798</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.105.535484</pub-id><pub-id pub-id-type="other">2-s2.0-27844538450</pub-id><pub-id pub-id-type="pmid">16246947</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>G.</given-names></name><name><surname>Finn</surname><given-names>A. V.</given-names></name><name><surname>Joner</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study</article-title><source><italic>Circulation</italic></source><year>2008</year><volume>118</volume><issue>11</issue><fpage>1138</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.107.762047</pub-id><pub-id pub-id-type="other">2-s2.0-54049125008</pub-id><pub-id pub-id-type="pmid">18725485</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virmani</surname><given-names>R.</given-names></name><name><surname>Guagliumi</surname><given-names>G.</given-names></name><name><surname>Farb</surname><given-names>A.</given-names></name><etal></etal></person-group><article-title>Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?</article-title><source><italic>Circulation</italic></source><year>2004</year><volume>109</volume><issue>6</issue><fpage>701</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000116202.41966.d4</pub-id><pub-id pub-id-type="other">2-s2.0-10744229988</pub-id><pub-id pub-id-type="pmid">14744976</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Császár</surname><given-names>A.</given-names></name></person-group><article-title>Anti-atherosclerotic effect of pioglitazone—the first evidence of the role of triglyceride/HDL ratio</article-title><source><italic>Lege Artis Medicinae</italic></source><year>2011</year><volume>21</volume><issue>2</issue><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="other">2-s2.0-79952931941</pub-id><pub-id pub-id-type="pmid">21710708</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waite</surname><given-names>K. J.</given-names></name><name><surname>Floyd</surname><given-names>Z. E.</given-names></name><name><surname>Arbour-Reily</surname><given-names>P.</given-names></name><name><surname>Stephens</surname><given-names>J. M.</given-names></name></person-group><article-title>Interferon-<italic>γ</italic>-induced regulation of peroxisome proliferator-activated receptor <italic>γ</italic> and STATs in adipocytes</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>2001</year><volume>276</volume><issue>10</issue><fpage>7062</fpage><lpage>7068</lpage><pub-id pub-id-type="doi">10.1074/jbc.m007894200</pub-id><pub-id pub-id-type="other">2-s2.0-0035831494</pub-id><pub-id pub-id-type="pmid">11106650</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Pioglitazone decreased plasma proinflammatory factors concentrations in patients after coronary DES implantation. The results are presented as raw data. Compared to the control group, PIO significantly reduced plasma IL-6, TNF-<italic>α</italic>, and MMP-9 concentrations by TWRMANOVA (<italic>P</italic> = 0.011, 0.008, 0.002, and 0.012, resp.). <sup><italic>∗</italic></sup>
<italic>P</italic> &lt; 0.05 compared with baseline.</p></caption><graphic xlink:href="PPAR2016-7407153.001"></graphic></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Pioglitazone downregulated the proinflammation in MNC. (a)–(c) Change in mRNA expression of peripheral blood mononuclear cells (MNC). The mRNA levels of IL-6, TNF-<italic>α</italic>, and MMP-9 were detected by quantitative real-time PCR. (d) NF-<italic>κ</italic>B DNA binding activity was detected. (e) The expression of p50 subunit and p65 subunit in MNC. <sup><italic>∗</italic></sup>
<italic>P</italic> &lt; 0.05 and <sup><italic>∗∗</italic></sup>
<italic>P</italic> &lt; 0.01 compared with baseline.</p></caption><graphic xlink:href="PPAR2016-7407153.002"></graphic></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Pioglitazone blocked the DES-induced PPAR-<italic>γ</italic> ubiquitination and degradation in vivo. (a) PPAR-<italic>γ</italic> DNA binding activity was shown. (b) PPAR-<italic>γ</italic> protein was tested by Western blot. (c) The mRNA expression of PPAR-<italic>γ</italic>. (d) The ubiquitination of PPAR-<italic>γ</italic> was detected by coimmunoprecipitation assay. <sup><italic>∗</italic></sup>
<italic>P</italic> &lt; 0.05, compared with baseline.</p></caption><graphic xlink:href="PPAR2016-7407153.003"></graphic></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the study population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameters</th><th align="center" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 14)</th><th align="center" rowspan="1" colspan="1">Pioglitazone (<italic>n</italic> = 14)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex, M/F, <italic>n</italic>/<italic>n</italic>
</td><td align="center" rowspan="1" colspan="1">11/3</td><td align="center" rowspan="1" colspan="1">12/2</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, yr</td><td align="center" rowspan="1" colspan="1">55.5 ± 10.9</td><td align="center" rowspan="1" colspan="1">56.2 ± 10.4</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">23.7 ± 4.9</td><td align="center" rowspan="1" colspan="1">24.5 ± 2.9</td><td align="left" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic BP, mm Hg</td><td align="center" rowspan="1" colspan="1">124 ± 19</td><td align="center" rowspan="1" colspan="1">121 ± 16</td><td align="left" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic BP, mm Hg</td><td align="center" rowspan="1" colspan="1">78 ± 10</td><td align="center" rowspan="1" colspan="1">76 ± 10</td><td align="left" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting glucose, mmol/L</td><td align="center" rowspan="1" colspan="1">5.28 ± 0.57</td><td align="center" rowspan="1" colspan="1">5.32 ± 0.37</td><td align="left" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c, %</td><td align="center" rowspan="1" colspan="1">5.42 ± 0.59</td><td align="center" rowspan="1" colspan="1">5.18 ± 0.49</td><td align="left" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol, mmol/L</td><td align="center" rowspan="1" colspan="1">3.78 ± 0.76</td><td align="center" rowspan="1" colspan="1">3.61 ± 0.45</td><td align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides, mmol/L</td><td align="center" rowspan="1" colspan="1">1.75 ± 1.27</td><td align="center" rowspan="1" colspan="1">1.81 ± 1.23</td><td align="left" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL cholesterol, mmol/L</td><td align="center" rowspan="1" colspan="1">0.90 ± 0.17</td><td align="center" rowspan="1" colspan="1">0.88 ± 0.20</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol, mmol/L</td><td align="center" rowspan="1" colspan="1">2.35 ± 0.67</td><td align="center" rowspan="1" colspan="1">2.15 ± 0.49</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Gensini score</td><td align="center" rowspan="1" colspan="1">12.6 ± 8.8</td><td align="center" rowspan="1" colspan="1">10.9 ± 5.1</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">hsCRP, mg/L</td><td align="center" rowspan="1" colspan="1">4.0 (0.8, 11.8)</td><td align="center" rowspan="1" colspan="1">2.9 (1.3, 12.3)</td><td align="left" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment after stenting</td><td align="center" rowspan="1" colspan="1"> </td><td align="center" rowspan="1" colspan="1"> </td><td align="left" rowspan="1" colspan="1"> </td></tr><tr><td align="left" rowspan="1" colspan="1"> Aspirin</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"> Clopidogrel</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"> Blocker</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1"> ACE inhibitors/ARBs</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"> Statins</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">1.00</td></tr></tbody></table><table-wrap-foot><fn><p>Data are reported as mean ± SD, median (interquartile range), or <italic>n</italic>. BP, blood pressure; hs-CRP, high sensitivity C-reactive protein; ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor blocker.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Metabolic and other parameters at baseline and after 12 weeks.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Parameters</th><th colspan="2" align="center" rowspan="1">Placebo controls</th><th colspan="2" align="center" rowspan="1">Pioglitazone</th></tr><tr><th align="center" rowspan="1" colspan="1">0 wk</th><th align="center" rowspan="1" colspan="1">12 wk</th><th align="center" rowspan="1" colspan="1">0 wk</th><th align="center" rowspan="1" colspan="1">12 wk</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">23.7 ± 4.9</td><td align="center" rowspan="1" colspan="1">23.3 ± 3.3</td><td align="center" rowspan="1" colspan="1">24.5 ± 2.9</td><td align="center" rowspan="1" colspan="1">24.7 ± 2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg</td><td align="center" rowspan="1" colspan="1">65.4 ± 12.7</td><td align="center" rowspan="1" colspan="1">66.7 ± 12.7</td><td align="center" rowspan="1" colspan="1">68.8 ± 9.4</td><td align="center" rowspan="1" colspan="1">69.3 ± 8.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist to hip ratio, %</td><td align="center" rowspan="1" colspan="1">89.1 ± 5.8</td><td align="center" rowspan="1" colspan="1">89.3 ± 5.6</td><td align="center" rowspan="1" colspan="1">89.9 ± 5.9</td><td align="center" rowspan="1" colspan="1">90.2 ± 5.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic BP, mm Hg</td><td align="center" rowspan="1" colspan="1">124 ± 19</td><td align="center" rowspan="1" colspan="1">126 ± 13</td><td align="center" rowspan="1" colspan="1">121 ± 16</td><td align="center" rowspan="1" colspan="1">121 ± 15</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic BP, mm Hg</td><td align="center" rowspan="1" colspan="1">78 ± 10</td><td align="center" rowspan="1" colspan="1">77 ± 8</td><td align="center" rowspan="1" colspan="1">76 ± 10</td><td align="center" rowspan="1" colspan="1">73 ± 9</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting glucose, mmol/L</td><td align="center" rowspan="1" colspan="1">5.28 ± 0.57</td><td align="center" rowspan="1" colspan="1">5.30 ± 0.49</td><td align="center" rowspan="1" colspan="1">5.32 ± 0.37</td><td align="center" rowspan="1" colspan="1">5.31 ± 0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting insulin, U/L</td><td align="center" rowspan="1" colspan="1">6.73 ± 3.98</td><td align="center" rowspan="1" colspan="1">6.10 ± 4.02</td><td align="center" rowspan="1" colspan="1">6.79 ± 4.44</td><td align="center" rowspan="1" colspan="1">5.21 ± 3.62</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c, %</td><td align="center" rowspan="1" colspan="1">5.42 ± 0.59</td><td align="center" rowspan="1" colspan="1">5.72 ± 0.46</td><td align="center" rowspan="1" colspan="1">5.18 ± 0.49</td><td align="center" rowspan="1" colspan="1">5.79 ± 0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol, mmol/L</td><td align="center" rowspan="1" colspan="1">3.78 ± 0.76</td><td align="center" rowspan="1" colspan="1">3.12 ± 0.74<sup><italic>∗∗</italic></sup>
</td><td align="center" rowspan="1" colspan="1">3.61 ± 0.45</td><td align="center" rowspan="1" colspan="1">3.01 ± 0.51<sup><italic>∗∗</italic></sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides, mmol/L</td><td align="center" rowspan="1" colspan="1">1.75 ± 1.27</td><td align="center" rowspan="1" colspan="1">1.38 ± 0.91<sup><italic>∗</italic></sup>
</td><td align="center" rowspan="1" colspan="1">1.81 ± 1.23</td><td align="center" rowspan="1" colspan="1">1.14 ± 0.39<sup><italic>∗</italic></sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL cholesterol, mmol/L</td><td align="center" rowspan="1" colspan="1">0.90 ± 0.17</td><td align="center" rowspan="1" colspan="1">1.16 ± 0.41<sup><italic>∗</italic></sup>
</td><td align="center" rowspan="1" colspan="1">0.88 ± 0.20</td><td align="center" rowspan="1" colspan="1">1.27 ± 0.41<sup><italic>∗∗</italic></sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol, mmol/L</td><td align="center" rowspan="1" colspan="1">2.35 ± 0.67</td><td align="center" rowspan="1" colspan="1">1.67 ± 0.40<sup><italic>∗∗</italic></sup>
</td><td align="center" rowspan="1" colspan="1">2.15 ± 0.49</td><td align="center" rowspan="1" colspan="1">1.69 ± 0.40<sup><italic>∗</italic></sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">hsCRP, mg/L</td><td align="center" rowspan="1" colspan="1">4.0 (0.9, 11.8)</td><td align="center" rowspan="1" colspan="1">2.2 (0.8, 6.8)<sup><italic>∗∗</italic></sup>
</td><td align="center" rowspan="1" colspan="1">2.9 (1.3, 12.3)</td><td align="center" rowspan="1" colspan="1">1.0 (0.5, 3.8)<sup><italic>∗∗</italic>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NT-pro BNP, pg/mL</td><td align="center" rowspan="1" colspan="1">220 (79, 839)</td><td align="center" rowspan="1" colspan="1">231 (140, 664)</td><td align="center" rowspan="1" colspan="1">259 (73, 706)</td><td align="center" rowspan="1" colspan="1">260 (102, 703)</td></tr><tr><td align="left" rowspan="1" colspan="1">EF, %</td><td align="center" rowspan="1" colspan="1">61.3 ± 9.9</td><td align="center" rowspan="1" colspan="1">62.7 ± 9.5</td><td align="center" rowspan="1" colspan="1">60.4 ± 8.1</td><td align="center" rowspan="1" colspan="1">60.6 ± 7.4</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic>n</italic> = 14 for each group. Values are mean ± SD or median (interquartile range).</p></fn><fn><p> 
<sup><italic>∗</italic></sup>
<italic>P</italic> &lt; 0.05 and <sup><italic>∗∗</italic></sup>
<italic>P</italic> &lt; 0.01 compared with baseline, and <sup>#</sup>
<italic>P</italic> &lt; 0.01, compared with the placebo group.</p></fn></table-wrap-foot></table-wrap></floats-group></article>